Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more
Market Cap & Net Worth: Alaunos Therapeutics Inc (TCRT)
Alaunos Therapeutics Inc (NASDAQ:TCRT) has a market capitalization of $6.96 Million ($6.96 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30971 globally and #10198 in its home market, demonstrating a -13.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alaunos Therapeutics Inc's stock price $3.12 by its total outstanding shares 2231829 (2.23 Million).
Alaunos Therapeutics Inc Market Cap History: 2015 to 2026
Alaunos Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $2.78 Billion to $6.96 Million (-45.17% CAGR).
Index Memberships
Alaunos Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #797 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2528 of 3165 |
Weight: Alaunos Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alaunos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alaunos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
425.16x
Alaunos Therapeutics Inc's market cap is 425.16 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.78 Billion | $4.33 Million | -$120.09 Million | 642.19x | N/A |
| 2016 | $1.79 Billion | $6.86 Million | -$165.30 Million | 261.05x | N/A |
| 2017 | $1.39 Billion | $6.39 Million | -$54.32 Million | 216.93x | N/A |
| 2018 | $626.03 Million | $146.00K | -$53.12 Million | 4287.86x | N/A |
| 2021 | $364.90 Million | $398.00K | -$78.75 Million | 916.84x | N/A |
| 2022 | $217.60 Million | $2.92 Million | -$37.73 Million | 74.47x | N/A |
| 2023 | $23.43 Million | $5.00K | -$35.14 Million | 4686.84x | N/A |
| 2024 | $4.25 Million | $10.00K | -$4.68 Million | 425.16x | N/A |
Competitor Companies of TCRT by Market Capitalization
Companies near Alaunos Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Alaunos Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Alaunos Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Alaunos Therapeutics Inc's market cap moved from $2.78 Billion to $ 6.96 Million, with a yearly change of -45.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.96 Million | -3.41% |
| 2025 | $7.21 Million | +69.55% |
| 2024 | $4.25 Million | -81.86% |
| 2023 | $23.43 Million | -89.23% |
| 2022 | $217.60 Million | -40.37% |
| 2021 | $364.90 Million | -56.75% |
| 2020 | $843.63 Million | -46.61% |
| 2019 | $1.58 Billion | +152.41% |
| 2018 | $626.03 Million | -54.83% |
| 2017 | $1.39 Billion | -22.62% |
| 2016 | $1.79 Billion | -35.62% |
| 2015 | $2.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Alaunos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.96 Million USD |
| MoneyControl | $6.96 Million USD |
| MarketWatch | $6.96 Million USD |
| marketcap.company | $6.96 Million USD |
| Reuters | $6.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.